The evolution of immune blockades in tumors limits successful antitumor immunity, but the mechanisms underlying this process are not fully understood. Depletion of regulatory T cells (Treg), a T-cell subset that dampens excessive inflammatory and autoreactive responses, can allow activation of tumor-specific T cells.
Introduction
Several laboratories have shown that CD4 þ CD25 þ Foxp3 þ regulatory T cells (Treg), which normally serve to control autoimmunity and inflammation, also inhibit immune responses to tumor antigens (1) . Thus, strategies aimed at boosting antitumor responses, through manipulation of Tregs, are being intensely investigated. In mice, prophylactic depletion of Tregs using CD25-specific antibodies can limit and even prevent tumor development and/or progression (2) (3) (4) . The development of transgenic mice expressing the primate diphtheria toxin receptor (DTR) on Foxp3 þ cells has allowed specific and complete depletion of Tregs by administration of diphtheria toxin (DT; 5). Using the melanoma cell line B16, it has been shown that selective Treg depletion using anti-CD25 antibodies (6) or DT (7) results in activation of a tumor-specific CD8 þ T-cell response and slower tumor growth. Use of the DTR-Foxp3 transgenic mice has also shown that Treg depletion can prevent development and even limit the progression of tumors induced by the carcinogen methylcholanthrene (MCA) in a manner that is dependent on CD8 þ T cells and IFNg (8) .
The success of these interventions however remains suboptimal. Treg depletion, even when combined with vaccination, does not readily result in the elimination of established tumors as tumor rejection is often observed in only a proportion of treated mice. Several factors, including the extent of T-cell activation and/or tumor infiltration, may account for this failure (6) . In this study, we set out to identify factors limiting the success of antitumor immune responses. For this purpose, we used the MCA chemical carcinogenesis model in combination with Foxp3 DTR mice (5) , to identify the key features that distinguish progressing tumors from those that are controlled after Treg depletion. Our findings clearly indicate that T-cell infiltration and not the extent of activation, is a critical bottleneck to tumor destruction in Tregdepleted animals. Moreover, our extensive immunohistochemical analyses of MCA-induced tumors from Tregreplete and Treg-depleted mice revealed that control of tumor growth, observed in Treg-depleted mice, was determined by development of high endothelial venules (HEV), specialized blood vessels that alter both the composition and size of the T-cell infiltrate (9, 10) . Overall, these data provide a new perspective on the impact of Treg depletion, demonstrating that Tregs control immune responses, not only through limiting immune activation, but also through influencing blood vessel differentiation.
Materials and Methods

Mice
We are grateful to Professor Alexander Rudensky for supplying Foxp3 DTR mice. These were backcrossed with C57BL/6 mice for 5 or more generations and housed in accordance with UK Home Office regulations.
Tumor induction, DT administration, and tumor monitoring Foxp3 DTR mice were injected subcutaneously in the left hind leg with 400 mg of 3-MCA (Sigma-Aldrich) in 100 mL of olive oil under general anesthetic as described previously (11) . Mice were monitored for tumor development weekly up to 2 months and daily thereafter. Tumor-bearing mice were culled before their tumors reached 1.7 cm in diameter, typically 80 to 150 days after injection or if tumors caused discomfort. DT (Sigma) diluted in PBS was administered intraperitoneally (i.p.) every other day after tumor detection.
Tumor growth rate (k, days
À1
) was determined using a statistical software package Prism 5 (GraphPad) with the following equation for exponential growth: Y ¼ Y0 Â exp(k Â X). Tumor diameter (X, mm) was measured every 2 days using calipers. On average, measurements were taken for 12 days for PBS-treated mice and 17 days for DT-treated mice. Therefore, on average 6 to 8 measurements were used to calculate tumor growth rate.
Flow cytometry
Single-cell suspensions of spleens, inguinal lymph nodes, and tumors were prepared. The inguinal lymph node from the tumor (left) side was taken as the tumor-draining lymph node and the contralateral inguinal lymph node as a nondraining lymph node.
For analysis of intracellular cytokines by flow cytometry, single-cell suspensions were stimulated with 20 ng/ml phorbol myristate acetate (Sigma-Aldrich) and 1 mg/mL ionomycin (Sigma-Aldrich). Cells were incubated at 37 C for a total of 4 hours. After 1 hour, 1 mL/mL of GolgiStop (containing monensin; Becton Dickinson) was added to each well.
To identify dead cells, a fixable dead cell staining kit (LIVE/ DEAD Aqua; Invitrogen) was used. Cells were washed twice in PBS and 3 to 6 mL of diluted (1:10; in PBS) dead cell stain was added to the cell pellet. Cells were stained at room temperature for 15 minutes in the dark then washed twice in fluorescenceactivated cell sorting (FACS) buffer (PBS containing 5 mM EDTA and 2% fetal calf serum). For surface-marker staining, fluorescently labeled mAbs: anti-CD4 Pacific Blue (Becton Dickinson), anti-CD8 PerCP-Cy5.5 (eBioscience), anti-CD25 PE (eBioscience) were used. Then cells were fixed, permeabilized, and stained for intracellular antigens using the Foxp3 Fix/Perm buffer set (eBioscience) and the following fluorescently labeled mAbs: anti-Foxp3 PE-Cy7 (eBioscience), antiKi67 Alexa Fluor 647 (Becton Dickinson), anti-IFNg APC (eBioscience), anti-IL2 PE (eBioscience), anti-granzyme B Alexa Fluor 647 (eBioscience), and anti-CD107a PE (eBioscience). For flow cytometric analysis, samples were acquired using a FACS Canto II flow cytometer (Becton Dickinson) and were analyzed using FACSDiva software (Becton Dickinson).
Immunohistochemistry
Paraffin sections. Tumors were collected from Foxp3 DTR mice and fixed in neutral buffered formalin and embedded in paraffin. Sections 5 mm in thickness, were cut and mounted on slides, dewaxed in xylene and hydrated using graded alcohols to tap water. After conducting antigen retrieval, by microwaving in 10 mmol/L Tris, 1 mmol/L EDTA buffer pH9 for 8 minutes, sections were cooled for 30 minutes and then equilibrated in PBS. Endogenous peroxidase activity was quenched with Peroxidase Suppressor (Thermo Scientific) for 15 minutes and nonspecific antibody binding was blocked by incubating sections with 2.5% normal horse serum (VectorLabs) in PBS for 30 minutes. Sections were stained overnight at 4 C with the following primary antibodies diluted in 1% bovine serum albumin (BSA) in PBS: rat antiperipheral node addressin (PNAd) antibody (clone MECA-79; Biolegend) and rat anti-Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody (clone MECA-367; Biolegend). Primary antibodies were detected with anti-rat Immpress (VectorLabs) for 30 minutes and visualized with impact 3,3 0 -diaminobenzidine (VectorLabs). Sections were counterstained with haematoxylin, dehydrated in an ethanol series, and mounted in distyrene, plasticizer, xylene. Photomicrographs were taken using a NIKON microscope and digital camera.
Frozen sections. Tumors and lymph nodes were collected from Foxp3 DTR mice, embedded in optimum cutting temperature compound (OCT; RA Lamb), and snap frozen in liquid nitrogen. Sections, 5 mm in thickness, were fixed for 10 minutes in ice-cold acetone and left to dry at room temperature. Slides were washed in PBS and blocked with Avidin/Biotin Blocking Kit (VectorLabs) and then 2.5% normal horse serum (VectorLabs) in PBS for 30 minutes. Sections were stained overnight at 4 C with the following primary antibodies diluted in 1% BSA in PBS: rat anti-PNAd antibody (clone MECA-79; Biolegend), Alexa Fluor 488 rat anti-MAdCAM-1 antibody (clone MECA-367; BioLegend), biotin rat anti-PNAd antibody (clone MECA-79; BioLegend), rat anti-CD4 (clone RM4-5; eBioscience), rat anti-CD8 (clone 53-6.7; eBioscience), fluorescein isothiocyanate rat anti-CD31 (clone 390; eBioscience), biotin rat anti-CD45R/B220 (clone RA3-6B2; eBioscience), rabbit anti-CD3 (DAKO), and rat anti-CD35 (clone 8C12; BD Pharmingen). Primary antibodies were detected with Alexa Fluor 488 goat anti-rat, Alexa Fluor 488 goat anti-rabbit, and streptavidinAlexa Fluor 555 (all from Invitrogen Life Sciences). When sections were double-stained with 2 unconjugated rat primary antibodies, the first rat primary antibody (anti-CD4 or -CD8) was detected with Alexa Fluor 488 anti-rat then fixed in 1% paraformaldehyde for 10 minutes before using a biotinylated second rat primary antibody (anti-PNAd), which was detected by streptavidin-Alexa Fluor 555. All sections were counterstained with TOTO-3 iodide (Invitrogen) before fixing with 1% paraformaldehyde for 10 minutes and mounting with Vectashield, containing 4', 6-diamidino-2-phenylindole (Vectorlabs). Images were collected with a Zeiss LSM5 Pascal confocal microscope. Images recorded in the far-red channel were pseudocolored blue. Images were assembled in Adobe Photoshop software.
Gene expression analysis
Samples were cut in 10 mm sections from OCT embedded tissue and RNA extracted using TRIzol reagent (Invitrogen). Gene expression profiling was carried out using MouseRef8v2.0 whole genome expression bead chip (Illumina) as recommended by the manufacturer. Probe intensity values were corrected by background subtraction in GenomeStudio software and subsequently log-2 and baseline (median) transformed using Genespring software (Agilent) before analysis of genes.
Statistical analyses
All statistical analyses were conducted using Prism 5 (GraphPad). Unless stated otherwise, data groups were compared using an unpaired, nonparametric Mann-Whitney test and displayed as median. Where stated, data groups were compared by an unpaired t test following confirmation that the set was normally distributed using the D'Agostino and Pearson omnibus normality test. In this instance the mean was graphed. Correlation analyses were conducted using the Pearson method and Pearson correlation coefficients (r 2 ) are displayed.
Results
Activation of tumor-infiltrating lymphocytes after Treg depletion and impact on tumor progression
Previously we have found that A highly significant reduction in tumor growth rate was observed in DT-treated (Treg-; n ¼ 43) compared with control-treated (Tregþ; n ¼ 24) mice (P ¼ 0.0008; Fig. 1 ) and tumor regression was observed in 12% (n ¼ 5) of mice (tumor growth rate <0; Fig. 1 ). However, despite the overall reduction in tumor growth rate, no difference in growth rate was observed in many of the treated mice. As T cells have been shown to control MCA-induced tumors following Treg depletion (7), we postulated that control of tumor growth would correlate with the extent of T-cell activation following depletion of Tregs. Indeed, analysis by flow cytometry revealed a highly significant increase in the percentage of both CD8 þ and CD4 þ T cells in the spleen and tumors of Treg-depleted compared with control mice (Supplementary Fig. S3 ). However, when we examined CD4 þ and CD8 þ tumor-infiltrating lymphocytes (TIL) for expression of the activation markers CD25 and Ki67 and also for functional markers, IFNg, IL-2, granzyme-B, and CD107a, we found no significant correlation between tumor growth rate and any of these markers ( Fig. 2 and Supplementary Fig. S4 ), indicating that following Treg-depletion, the extent of CD8 þ or CD4 þ T-cell activation is not a critical bottleneck to successful control of tumor growth. We also evaluated whether tumor size at the start of treatment correlated with treatment success. The data, shown in Fig. 3 , clearly indicate that this is not the case, as the impact of Treg depletion on tumor growth kinetics was not influenced by the size of the tumor at the start of treatment.
Tumor control is associated with accumulation of TILs Next, we addressed whether the extent of T-cell infiltration following Treg depletion was associated with control of tumor growth. To enumerate tumor-infiltrating T cells, we conducted extensive immunohistochemical analyses of 14 Treg-and 8 control, Tregþ tumors with representative examples of CD8-and CD4-specific staining shown in Fig. 4A and B. A significant increase in the number of CD8 þ cells (P ¼ 0.0140) and an overall increase in the number of CD4 þ cells (P ¼ 0.0818) was observed in the tumors of Treg-versus control Tregþ mice ( Fig. 4C and D) . However, the accumulation of tumor infiltrating T cells was not universal among treated mice, as many of these did not differ significantly from the control group ( Fig. 4C  and D) . Indeed, the Treg-mice could clearly be split into 2 subgroups: those with less than 100 (TIL lo ) and those with greater than 100 (TIL hi ) CD4 þ or CD8 þ cells per high-power field (Fig. 4A-D ). The correlation between the level of CD8 þ and CD4
þ cell infiltration and tumor growth rate in Treg-mice was striking (P ¼ 0.0238 and P ¼ 0.0047, respectively; Fig. 4E and F) whereas no correlation was observed in control Tregþ mice ( Fig. 4G and H) . Although we do not rule out a role for T cells in controlling tumors in any Tregþ tumor (particularly those with lower growth rates), these data indicate that following Treg-depletion, T-cell infiltration determines successful control of tumor growth. HEV neogenesis in Treg-depleted, but not Treg-replete tumors
We hypothesized that those tumors that are controlled after depleting Tregs would differ from those that continue to progress with respect to mechanisms governing T-cell trafficking. Thus, tumors were examined by immunohistochemistry for markers associated with HEVs, specialized postcapillary venules found in secondary lymphoid tissues that facilitate extravasation of naive and central memory T cells from blood to lymphoid organs (9) . For this purpose, tumors were stained using antibody clone MECA-79, which recognizes PNAd, a carbohydrate epitope expressed on a variety of L-selectin ligands that is specifically expressed by HEV (12) . No PNAd staining was observed in any of the tumors recovered from Tregþ control animals (Fig. 5A, n ¼ 14) . However, PNAd staining was identified in 50% of tumors recovered from animals depleted of Treg (Fig. 5B-E, n ¼ 14) . The cuboidal morphology of the cells (arrowhead) expressing PNAd in the tumors was consistent with HEV morphology (Fig. 5D) . Furthermore, PNAd expression often colocalized with MAd-CAM-1, an HEV-associated molecule, normally expressed on immature HEV, adult mucosal lymphoid tissue, and lamina Fig. S5 ; [18] [19] [20] . Collectively, these data indicate that although HEV neognesis is accompanied by expression of the lymphoid chemokines CCL19, CCL21, and CXCL13, it takes place without the need for LTi cells or for lymphoid neo-organogenesis. It is however possible that HEV development and expression of lymphoid chemokines represent the early stages of this process, preceding development of TLO.
HEV neogenesis promotes T-cell infiltration and tumor control HEV neogenesis has been reported in the context of chronic inflammation and autoimmune disease in both mouse models and human disease (9, 21, 22) . Consistent with their ability to facilitate increased lymphocyte extravasation, HEV are found in regions of extensive lymphocytic infiltrate. Thus, we compared the number of tumor-infiltrating T cells in HEVþ and HEV-tumors. A clear association was observed between presence of HEV within tumor tissue and a high number of CD8 þ T cells ( Fig. 7A ; P ¼ 0.0034). When we compared the presence of HEV with tumor growth rate, HEVþ tumors showed significantly reduced tumor growth rate compared with HEV-tumors ( Fig. 7B ; P ¼ 0.0082). Interestingly, no correlation was observed between the extent of CD31 staining and numbers of CD8 þ T cells, indicating that the development of HEV and not blood vessel development per se, is central to the increase in T-cell infiltration and control of tumor growth (Fig. 7C) . In support of the premise that tumor HEV allow the infiltration of T cells into the tissue, we frequently found T cells attached to or extravasating through the luminal wall of the vessel ( Fig. 7D and E, arrowheads) . Moreover, when expression of CD3, CCR7, L-Selectin, and the transcription factor, KLF2 were assessed and compared between HEVand HEVþ tumors, there was a clear increase in the expression of these molecules in the HEVþ tumors (Fig. 7F) . Thus, these data suggest that development of HEV in tumors, allows infiltration of L-selectin hi CCR7 þ T cells, which includes both central memory and naive T cells. In support of this, we have observed clonal expansion within tumor-infiltrating T cells, suggesting that an antigen-driven response is generated intratumorally (Supplementary Fig.  S6 ). Overall, these data strongly support the premise that following Treg depletion, the formation of HEV shapes the size and composition of the T-cell infiltrate resulting in tumor control.
Discussion
Selective depletion of Foxp3 þ Tregs can result in immunemediated control of tumors. We examined the distinguishing features of controlled versus progressing tumors following therapeutic Treg depletion in mice bearing palpable carcinogen-induced tumors. Previously, using the tumor cell line, B16, it was reported that although Treg-depletion promoted systemic T-cell activation (as also shown above), control of tumor growth was limited by failure of the T cells to infiltrate the tumor (6). In this and previous studies, it was shown that sensitizing the tumor stroma through irradiation or inflammation, induced vascular remodeling and upregulation of adhesion molecules facilitating T-cell infiltration into tumors (6, 23) . The data presented herein identify, for the first time, a previously unsuspected effect of Treg-depletion in facilitating neogenesis of HEV, which enable T-cell recruitment into the tumor from blood. The significance of this effect is striking: HEV are not observed unless Tregs are depleted and there is an absolute concordance between presence of HEV, high numbers of tumor-infiltrating T lymphocytes, and control of tumor growth. As yet, we have not identified the mechanisms underpinning HEV neogenesis in tumors. Under nonpathologic conditions, HEV development is confined to secondary lymphoid tissue. Ligation of the LTb receptor (LTbR) on stromal-organiser cells by LTab expressing LTi cells represents a key event in the development of lymph nodes (18, 19) . Although LTbR signaling is required to maintain fully differentiated HEV (24, 25), mechanisms underpinning HEV formation in lymph nodes and whether they are related to those driving stromal cell differentiation remain incompletely defined. HEV neogenesis within chronically inflamed tissue was first reported around 15 years ago and more recently in tumors (26) (27) (28) . As in lymph nodes, the presence of HEV is almost always associated with the development of a stromal cell network that organizes infiltrating lymphocytes into discrete T-and B-cell areas in socalled TLO (29) (30) (31) . However, the mechanisms underlying HEV neogenesis and how it relates to the development of the stromal cell network of TLO are poorly defined. In the case of the HEVþ tumors described in this study, although we have found no evidence of LTi cells or TLOs, expression of inflammatory cytokines and lymphoid chemokines is increased. Collectively these data imply that HEV neogenesis in tumors occurs through mechanisms that promote inflammation (in this case, Treg depletion) and deviate from those operating in secondary lymph nodes, possibly in terms of the cellular source of LTab.
An unexplained aspect of our findings is that HEV development, although tightly linked to Treg depletion, is only observed in around half of Treg-depleted mice. Several explanations may account for this finding, an exploration of which may offer vital clues to defining the mechanisms underpinning HEV neogenesis in tumors. First, the nature of the immune response stimulated following Treg depletion may affect whether HEV develop or not. Perhaps, following Treg depletion, T cells and/or B cells in some, but not all mice, produce important HEV inducing factors (e.g., LTab). Furthermore, the tumor may specifically impinge on the type of immune response induced following Treg depletion. Tumors that retain immunogenicity, perhaps as a result of Treg-induced immunosuppression, may activate tumor-specific T and B cells, which, as described above, drive HEV development. On the other hand, tumors that have escaped the attention of the immune system through the loss of strong antigens (immunoediting), may fail, even after Treg depletion, to induce a sufficiently robust, HEV-promoting immune response. Indeed, Matsushita and colleagues recently showed that the outgrowth of MCA-induced tumors could result from T-cell dependent selection of tumors lacking strong antigens (32) . Alternatively, tumor-intrinsic features may influence HEV development in a stochastic fashion. For instance, tumors may produce factors that either actively inhibit or facilitate HEV development. Gaining an understanding of these complex issues will uncover the mechanisms underpinning HEV neogenesis in tumors and facilitate a better understanding of whether a given immune response can promote tumor immunity through blood vessel differentiation.
The importance of understanding how HEV can develop in peripheral sites has clear implications for cancer immunotherapy. Recently, in a study of more than 300 human tumors, Martinet and colleagues discovered a highly significant association between the presence of HEV and the frequency of tumor-infiltrating T cells (26) . Moreover, when a cohort of around 150 breast cancer patients were investigated, the same study reported a significant correlation between HEV and a favorable prognosis. These data support a crucial role for HEV neogenesis in tumor rejection. Our study highlights one avenue toward achieving this goal, namely the depletion of Tregs. It would be extremely interesting therefore to examine whether in large cohorts of human tumors such as those used in the above studies, there is an inverse association between Tregs and the presence of HEV.
Although the precise mechanism of HEV induction in our study remains to be elucidated, the significant increase in expression of LTb in HEVþ tumors and the previously described role for LTab in maintaining fully functional HEV, support an important role for this cytokine. A study by Schrama and colleagues showed that administration of an LTa fusion protein into B16 melanoma-bearing mice resulted in HEV neogenesis, which subsequently promoted entry of naive T cells that were primed intratumorally and which contributed to tumor destruction (10) . Similarly, Yu and colleagues reported the same effect in mice inoculated with LIGHT-expressing tumors; this effect was attributed to the ability of LIGHT, such as LTa to facilitate generation of lymphoid structures, which enabled entry of naive T cells into the tumor (33) . In both cases, this resulted in efficient priming of tumor-specific T cells, presumably because of the high probability of these T cells meeting their cognate antigen within the tumor mass. We suggest that depleting Tregs can lead to HEV neogenesis; a process that is critical in determining the composition and size of the T-cell infiltrate thus permitting tumor destruction. Although the mechanisms of HEV induction and the influence of Tregs on this process are poorly understood, it is clear that a better understanding of these mechanisms will present new opportunities for more effective antitumor therapy. Furthermore, HEV neogenesis may play deleterious role in autoimmunity and chronic inflammation (9) . Our findings may therefore point to a hitherto unidentified mechanism through which a defect in Treg activity drives autoimmune disease and chronic inflammation by allowing HEV induction, hence sustained immune cell infiltration and destruction of the affected tissue. Harnessing this activity of Tregs therefore has implications for both cancer 
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